CDER’s Progress in Rare Diseases
Orphanet Journal of Rare Diseases is proud to present this piece, authored by the Rare Diseases Team within the U.S. Food & Drug Administration’s (FDA)… Read more »
The Division of Rare Diseases and Medical Genetics (DRDMG) serves as a hub for rare disease drug development across the Office of New Drugs by coordinating rare disease education, policy, research and stakeholder engagement. DRDMG also regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics License Applications (BLAs) for drugs and biologics intended for the prevention and treatment of rare inborn errors of metabolism.
Latest posts by FDA, Center for Drug Evaluation and Research (CDER) (see all)
- CDER’s Progress in Rare Diseases - 25th February 2021